
Cizzle Biotechnology: News flow driven by deals
Cizzle Biotechnology Holdings plc (LON:CIZ), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for early detection of different forms of

Cizzle Biotechnology Holdings plc (LON:CIZ), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for early detection of different forms of

Cizzle Biotechnology plc (LON:CIZ), the UK based diagnostics developer, has announced that it has executed a Memorandum of Understanding (“MOU”) with the International Co-Innovation Centre for Advanced Medical Technology and Shenzhen

Cizzle Biotechnology plc (LON:CIZ), the UK based diagnostics developer, has announced it has executed a research and development agreement to develop a companion diagnostic test for autoimmune disease with St

Cizzle Biotechnology Holdings PLC (LON:CIZ), the UK based diagnostics developer, has announced its results for the six months ended 30th June 2021. Highlights · Completed the acquisition of Cizzle Biotechnology Limited (“CBL”) on

Cizzle Biotechnology plc (LON:CIZ), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for early detection of different forms of lung

Cizzle Biotechnology plc (LON:CIZ), the UK based diagnostics developer, has announced it has executed a royalty sharing agreement with St George Street Capital, the UK-based biomedical charity. As announced on

Cizzle Biotechnology plc (LON:CIZ), the UK based diagnostics developer, has announced that it has entered into a new research agreement with the University of York for the development and validation of molecular

Cizzle Biotechnology plc (LON:CIZ), the UK based diagnostics developer, has provided an update on its collaboration with St George Street Capital, the UK-based biomedical charity. As announced on 22 June 2021,

Cizzle Biotechnology’s Allan Syms discusses their collaboration with FairJourney Biologics and the company’s main focus over the next 6 months in this exclusive interview with DirectorsTalk.

Cizzle Biotechnology plc (LON:CIZ) Executive Chairman Allan Syms joins DirectorsTalk to discuss a collaboration with FairJourney Biologics. Allan explains what this collaboration will cover, what will it mean for Cizzle